Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Immunovant (IMVT) Assets Average (2019 - 2026)

Immunovant filings provide 7 years of Assets Average readings, the most recent being $817.7 million for Q4 2025.

  • Quarterly Assets Average rose 74.6% to $817.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $817.7 million through Dec 2025, up 74.6% year-over-year, with the annual reading at $721.3 million for FY2025, 34.54% up from the prior year.
  • Assets Average hit $817.7 million in Q4 2025 for Immunovant, up from $622.2 million in the prior quarter.
  • Across five years, Assets Average topped out at $817.7 million in Q4 2025 and bottomed at $321.6 million in Q3 2023.
  • Average Assets Average over 5 years is $524.3 million, with a median of $494.4 million recorded in 2022.
  • The largest annual shift saw Assets Average soared 258.26% in 2021 before it dropped 27.46% in 2023.
  • Immunovant's Assets Average stood at $555.0 million in 2021, then dropped by 20.32% to $442.2 million in 2022, then increased by 13.47% to $501.8 million in 2023, then dropped by 6.66% to $468.3 million in 2024, then skyrocketed by 74.6% to $817.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Assets Average are $817.7 million (Q4 2025), $622.2 million (Q3 2025), and $718.8 million (Q2 2025).